ccRCC clinical trials at University of California Health

1 in progress, 0 open to eligible people

Showing trials for

  • Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC

    Sorry, not yet accepting patients

    Multicenter Phase 2A study of 177Lu-TLX250 in adult participants with CAIX-expressing advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC). Part 1 will evaluate two dosing regimens to determine the recommended Phase 3 dose (RP3D).

    at UCSD

Last updated: